A new experimental weight-loss pill has posted strong results in early clinical testing, adding another contender to the fast-growing race for an effective oral alternative to injectable GLP-1 drugs like Ozempic and Wegovy.
The drug, called aleniglipron, helped adults with obesity or overweight lose as much as 12.1% of their body weight over 36 weeks in a Phase 2b clinical trial, according to results published in Nature Medicine and reported by Northwestern Medicine on 10 August 2026.
What makes it different
Most GLP-1 medications on the market today — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are peptide-based drugs that have to be injected. Aleniglipron takes a different chemical approach entirely: it’s a small-molecule drug, meaning it’s chemically synthesised rather than built from a peptide, and can be taken as a pill once a day, with or without food.
Robert Kushner, professor emeritus of medicine at Northwestern’s Feinberg School of Medicine and a co-author of the study, explained why that distinction matters. Most everyday medications — aspirin, blood pressure pills — are small molecules, he noted, and because they’re chemically manufactured rather than biologically derived, they can potentially be produced more easily at scale and combined with other medications more readily than injectable peptides.
That manufacturing and access angle is a big part of the appeal. Injectable GLP-1 drugs require refrigeration, needles, and complex peptide manufacturing — all of which add cost and create access barriers for patients. A pill that skips all of that could, in theory, be cheaper and easier to distribute at the scale needed to meet the enormous global demand for these medications.
Inside the trial
The Phase 2b trial was randomised, double-blind, and placebo-controlled, run across 38 medical centres in the United States. It enrolled 230 adults with obesity or overweight, with an average age of 50.
Participants were split into three dose groups — 45mg, 90mg, or 120mg — taken orally once daily, with doses gradually increased every four weeks, or given a placebo. Treatment ran for 36 weeks total.
The results, by dose:
- 45mg group: −9.0% average body weight change
- 90mg group: −10.7% average body weight change
- 120mg group: −12.1% average body weight change
- Placebo group: −0.5% average body weight change
The effect was clearly dose-dependent, with higher doses producing greater weight loss — a pattern consistent with other GLP-1 drugs in this class.
Safety profile
Gastrointestinal side effects — the most common issue with this entire drug class — were reported as generally mild to moderate, and became less frequent as the trial progressed. Around 10.4% of participants discontinued treatment, and researchers reported no cases of drug-induced liver injury.
Kushner described the safety data as reassuring: no new safety signals emerged, and the trial identified a dose that appears effective. For the upcoming Phase 3 trial, researchers plan to slow the dose-escalation schedule further, aiming to improve tolerability as the drug moves toward larger-scale testing.
Where it fits in a crowded field
Aleniglipron now joins a growing list of oral GLP-1 candidates competing for a share of the obesity drug market, including Eli Lilly’s already-approved orforglipron and Novo Nordisk’s oral semaglutide pill. Unlike those two, which are further along in development and already reaching patients, aleniglipron is still in Phase 2 — meaning a Phase 3 trial, and likely a few more years, stand between it and any potential approval.
The trial was funded by Structure Therapeutics, the company developing the drug.
The bigger picture
Aleniglipron’s results won’t replace injectable GLP-1 drugs anytime soon, and 12% weight loss trails what the strongest injectable options (like tirzepatide, and the investigational triple-agonist retatrutide) have achieved in trials. But it adds further weight to a broader trend reshaping the obesity drug market in 2026: the shift toward oral, small-molecule formulations that could make GLP-1 therapy cheaper, easier to manufacture, and more accessible to the millions of patients currently priced out or unable to access injectable versions.
References
- Northwestern Medicine, via ScienceDaily. “New GLP-1 pill delivers up to 12% weight loss in 36 weeks.” 10 August 2026. Available at: https://www.sciencedaily.com/releases/2026/08/260810015717.htm
- Rosenstock, J., Lingvay, I., Ryan, D., Jastreboff, A.M., Kushner, R., et al. “Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.” Nature Medicine, 2026. DOI: 10.1038/s41591-026-04476-6
- Northwestern University Feinberg School of Medicine. “New GLP-1 drug promotes weight loss in obesity.” Available at: https://news.feinberg.northwestern.edu/2026/06/24/new-glp-1-drug-promotes-weight-loss-in-obesity/